staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad
Company profile
Ticker
STAA
Exchange
Website
CEO
Caren Mason
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
STAAR SURGICAL COMPANY
SEC CIK
Corporate docs
Subsidiaries
STAAR Surgical UK LTD • STAAR Surgical AG • STAAR Japan Inc. • STAAR Surgical PTE. LTD • Technology (Shanghai) Co., LTD • STAAR Surgical CHINA CO., LTD • STAAR Surgical India Private Limited ...
IRS number
953797439
STAA stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
18 Mar 24
8-K
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
12 Mar 24
8-K
Regulation FD Disclosure
28 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
26 Feb 24
8-K
STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023
8 Jan 24
8-K
Lilian Zhou Appointed to STAAR Surgical Board of Directors
4 Dec 23
8-K
Regulation FD Disclosure
16 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Regulation FD Disclosure
2 Nov 23
Transcripts
STAA
Earnings call transcript
2023 Q4
26 Feb 24
STAA
Earnings call transcript
2023 Q3
1 Nov 23
STAA
Earnings call transcript
2023 Q2
2 Aug 23
STAA
Earnings call transcript
2023 Q1
3 May 23
STAA
Earnings call transcript
2022 Q4
21 Feb 23
STAA
Earnings call transcript
2022 Q3
2 Nov 22
STAA
Earnings call transcript
2022 Q2
11 Aug 22
STAA
Earnings call transcript
2022 Q1
4 May 22
STAA
Earnings call transcript
2021 Q4
24 Feb 22
STAA
Earnings call transcript
2021 Q3
4 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Jan 21 | Jan 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 127.43 mm | 127.43 mm | 127.43 mm | 127.43 mm | 127.43 mm | 127.43 mm |
Cash burn (monthly) | (no burn) | 150.83 k | (no burn) | (no burn) | 1.99 mm | 1.20 mm |
Cash used (since last report) | n/a | 903.83 k | n/a | n/a | 11.93 mm | 7.19 mm |
Cash remaining | n/a | 126.53 mm | n/a | n/a | 115.50 mm | 120.24 mm |
Runway (months of cash) | n/a | 838.9 | n/a | n/a | 58.0 | 100.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 217 |
Opened positions | 35 |
Closed positions | 62 |
Increased positions | 94 |
Reduced positions | 62 |
13F shares | Current |
---|---|
Total value | 2.13 tn |
Total shares | 61.75 mm |
Total puts | 360.80 k |
Total calls | 198.30 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
Broadwood Capital | 9.26 mm | $372.24 bn |
Broadwood Partners | 8.59 mm | $0.00 |
BLK Blackrock | 8.03 mm | $322.59 bn |
Vanguard | 5.43 mm | $218.00 bn |
Baillie Gifford & Co | 4.92 mm | $197.61 bn |
Anatole Investment Management | 2.10 mm | $84.43 bn |
Jackson Square Partners | 2.09 mm | $83.79 bn |
STT State Street | 1.85 mm | $74.38 bn |
Palo Alto Investors | 1.37 mm | $55.24 bn |
Geode Capital Management | 1.01 mm | $40.43 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Weisner Aimee S | Common Stock | Buy | Acquire P | No | No | 38.11 | 1,750 | 66.69 k | 10,864 |
12 Mar 24 | Patrick F. Williams | Common Stock Options Common Stock | Grant | Acquire A | No | No | 37.64 | 21,908 | 824.62 k | 21,908 |
12 Mar 24 | Patrick F. Williams | RSU Common Stock | Grant | Acquire A | No | No | 0 | 24,460 | 0.00 | 24,460 |
12 Mar 24 | Arthur C Butcher | Common Stock | Grant | Acquire A | No | No | 0 | 649 | 0.00 | 649 |
12 Mar 24 | Arthur C Butcher | Common Stock Options Common stock | Grant | Acquire A | No | No | 37.64 | 1,163 | 43.78 k | 1,163 |
News
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
Netflix To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
11 Mar 24
Stifel Upgrades Staar Surgical to Buy, Raises Price Target to $50
11 Mar 24
Mizuho Maintains Buy on Staar Surgical, Lowers Price Target to $45
28 Feb 24
Piper Sandler Maintains Neutral on Staar Surgical, Lowers Price Target to $33
27 Feb 24
Press releases
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
12 Mar 24
STAAR Surgical to Participate in Two Upcoming Investor Conferences
6 Mar 24
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
19 Feb 24
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
23 Jan 24
STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023
8 Jan 24